|
rs1042522
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Results indicated that Arg72Pro is associated with higher susceptibility to cancer in some tumor sites, mainly hepatocarcinoma.
|
20886596 |
2011 |
|
rs1042522
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
To evaluate the significance of the TP53 mutation as a molecular marker to predict the prognosis of CRC patients, especially those who received postoperative chemotherapy, we examined the mutation by direct sequencing from fresh CRC tumors and evaluated the R72P polymorphism of the mutated TP53 by a combined mutant allele- and polymorphic allele-specific polymerase chain reaction (PCR).
|
19954513 |
2009 |
|
rs1042522
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
ERCC1 Lys259Thr (rs735482), ERCC2 Lys751Gln (rs13181), ERCC5 His46His C>T (rs1047768), XRCC1 Arg399Gln (rs25487), TP53 Arg72Pro (rs1042522) and MDM2 309T>G (rs2279744) were analyzed on tumor DNA.
|
28351583 |
2017 |
|
rs1042522
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Polymorphisms were identified within the TP53 (R72P and Ins16) and MDM2 (SNP309) genes that may further diminish TP53 tumor suppressor activity.
|
19046423 |
2008 |
|
rs1042522
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Statistically significant associations were noted between SNPs in beta-catenin and APOE and a positive family history of cancer (beta-catenin: p=0.034, APOE: p=0.033); tumor location and a DCC SNP (p=0.038) and the P53 R72P mutation and survival (p=0.0336).
|
15523694 |
2005 |
|
rs1042522
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We here studied the association of rs1219648 in FGFR2 and rs1042522 in TP53 and their interaction in development of early onset sporadic breast cancer in Iranian Azeri population to evaluate epistatic effects on the risk of mammary neoplasia.
|
25292094 |
2014 |
|
rs1042522
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The TP53 R72P polymorphism was not linked to tumor location, histologic grade, lymph node metastases, Dukes stage, p53 positivity, or age at diagnosis, but to tumor size.
|
17599946 |
2007 |
|
rs1042522
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome.
|
16258005 |
2006 |
|
rs1042522
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In addition, the TP53 R72P polymorphism and chromosome 1p/19q status, a major biomarker in oligodendroglial t</span>umors, were investigated.
|
18262501 |
2008 |
|
rs1042522
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Patients who had the allele Pro of the TP53 Arg72Pro polymorphism had an increased risk of tumor development (odds ratio, OR = 3.23; confidence interval at 95%, 95%CI = 1.71-6.08; P = 0.003), as did the allele Ser of TP53 Pro47Ser polymorphism (OR = 1.28; 95%CI = 0.03-2.10; P = 0.01).
|
19224462 |
2009 |
|
rs1042522
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The HPV E6 oncoprotein binds to the tumor suppressor gene product p53, promoting its degradation; the Arg allele of p53 Arg72Pro polymorphism binds more ardently with HPV E6 than the Pro variant.
|
23065429 |
2012 |
|
rs1042522
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Genetic data revealed that the p53 Arg72Pro genotype was found to be greatly associated with breast cancer risk (p<0.001), as well as tumor site (p=0.046).
|
25750340 |
2015 |
|
rs1042522
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The polymorphism rs1042522 at codon 72 of the TP53 tumour-suppressor gene has been investigated as a genetic cofactor.
|
19625214 |
2009 |
|
rs1042522
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
There have been inconsistent reports regarding increased risk of POAG and a polymorphism (Arg72Pro) within the tumor suppressor gene, p53.
|
19784392 |
2009 |
|
rs1042522
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Tissue culture and mouse model studies show that the presence of the arginine (R) or proline (P) coding single nucleotide polymorphism (SNP) of the tumor suppressor gene p53 at codon 72 (p53 R72P) differentially affects the responses to genotoxic insult.
|
28594296 |
2017 |
|
rs1042522
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The germ-line polymorphisms TP53 Arg72Pro and MDM2 SNP309 T>G are risk factors for tumor development and affect response to chemotherapy and survival in several cancers, but their prognostic and predictive value in patients with high-grade osteosarcomas is not yet defined.
|
19451596 |
2009 |
|
rs1042522
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results suggest that polymorphism Arg72Pro in tumor suppressor gene TP53 increases the risk of lung cancer.
|
18336951 |
2008 |
|
rs1042522
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Recently a polymorphism at codon 72 (R72P) in the tumour suppressor gene TP53 has been implicated in the age of disease onset in HNPCC.
|
16353134 |
2006 |
|
rs1042522
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
There was no evidence of such an effect on survival within the TP53-mutated tumor group for TP53 R72P carriers but a suggestion of an effect for MDM2 SNP309 carriers (GG vs. TT-genotype HR 2.99, P = 0.06).
|
21667122 |
2011 |
|
rs1042522
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We identified the presence of LOH at 17p13 and Pro72Arg polymorphism in tumor DNA.
|
12684657 |
2003 |
|
rs1042522
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In addition, we showed that BC patients with rs1042522 CC genotype were characterized by only unifocal tumors and decreased frequency of lymph node metastases (p=0.03).
|
21810023 |
2011 |
|
rs1042522
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Single nucleotide polymorphisms (SNP) in codon Arg72Pro of P53 results in impairment of the tumor suppressor activity of the gene.
|
23167335 |
2012 |
|
rs1042522
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness.
|
20535124 |
2010 |
|
rs1042522
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The analyses indicate that MDM2 SNP309 serves as a tumor susceptibility marker, and that there is an association between MDM2 SNP309 and p53 Arg72Pro regarding tumor susceptibility.
|
21619694 |
2011 |
|
rs1042522
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Studies on the association of a polymorphism in codon 72 of the p53 tumour suppressor gene (rs1042522) with cervical neoplasia have inconsistent results.
|
23441193 |
2013 |